Journal: Endocrinology and Metabolism

Article Title: Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis

doi: 10.3803/EnM.2020.818

Figure Lengend Snippet: Characteristics of Patients in the Randomised Controlled Trials Evaluated in this Meta-Analysis on the Use of Gemigliptin in Type 2 Diabetes Mellitus

Article Snippet: Gemigliptin was comparable to the ACG (metformin or sitagliptin) regarding the percent of patients achieving HbA1c <7% after 24 weeks of therapy (OR, 0.92; 95% CI, 0.52 to 1.63; P =0.77; I 2 =66% [moderate heterogeneity]; MCE) ( ).

Techniques: Control

Journal: Endocrinology and Metabolism

Article Title: Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis

doi: 10.3803/EnM.2020.818

Figure Lengend Snippet: Characteristics of Patients in the Studies Evaluated for, but Excluded from, This Meta-Analysis

Article Snippet: Gemigliptin was comparable to the ACG (metformin or sitagliptin) regarding the percent of patients achieving HbA1c <7% after 24 weeks of therapy (OR, 0.92; 95% CI, 0.52 to 1.63; P =0.77; I 2 =66% [moderate heterogeneity]; MCE) ( ).

Techniques: Control, Modification, Transplantation Assay

Journal: Endocrinology and Metabolism

Article Title: Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis

doi: 10.3803/EnM.2020.818

Figure Lengend Snippet: Summary of Findings: Gemigliptin Compared to Control in the Management of Type 2 Diabetes Mellitus

Article Snippet: Gemigliptin was comparable to the ACG (metformin or sitagliptin) regarding the percent of patients achieving HbA1c <7% after 24 weeks of therapy (OR, 0.92; 95% CI, 0.52 to 1.63; P =0.77; I 2 =66% [moderate heterogeneity]; MCE) ( ).

Techniques: Control

Journal: Endocrinology and Metabolism

Article Title: Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis

doi: 10.3803/EnM.2020.818

Figure Lengend Snippet: Forest plot highlighting the impact of gemigliptin as compared to the active control group after 24 weeks of therapy on (A) haemoglobin A1c (HbA1c), (B) fasting glucose, (C) the percent of people achieving HbA1c <7%, (D) the percent of people achieving HbA1c less than 6.5%. SD, standard deviation; IV, inverse variance; CI, confidence interval; M-H, Mantel-Haenszel.

Article Snippet: Gemigliptin was comparable to the ACG (metformin or sitagliptin) regarding the percent of patients achieving HbA1c <7% after 24 weeks of therapy (OR, 0.92; 95% CI, 0.52 to 1.63; P =0.77; I 2 =66% [moderate heterogeneity]; MCE) ( ).

Techniques: Control, Standard Deviation

Journal: Endocrinology and Metabolism

Article Title: Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis

doi: 10.3803/EnM.2020.818

Figure Lengend Snippet: Forest plot highlighting the impact of gemigliptin as compared to the passive control group after 24 weeks of therapy on (A) haemoglobin A1c (HbA1c), (B) fasting glucose, (C) the percent of people achieving HbA1c <7%, (D) the percent of people achieving HbA1c less than 6.5%. SD, standard deviation; IV, inverse variance; CI, confidence interval; M-H, Mantel-Haenszel.

Article Snippet: Gemigliptin was comparable to the ACG (metformin or sitagliptin) regarding the percent of patients achieving HbA1c <7% after 24 weeks of therapy (OR, 0.92; 95% CI, 0.52 to 1.63; P =0.77; I 2 =66% [moderate heterogeneity]; MCE) ( ).

Techniques: Control, Standard Deviation

Journal: Endocrinology and Metabolism

Article Title: Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis

doi: 10.3803/EnM.2020.818

Figure Lengend Snippet: Forest plot highlighting the side effect profile of the use of gemigliptin as compared to controls focussing on (A) total adverse events, (B) severe adverse events, (C) total hypoglycaemic episodes, (D) death. M-H, Mantel-Haenszel; CI, confidence interval.

Article Snippet: Gemigliptin was comparable to the ACG (metformin or sitagliptin) regarding the percent of patients achieving HbA1c <7% after 24 weeks of therapy (OR, 0.92; 95% CI, 0.52 to 1.63; P =0.77; I 2 =66% [moderate heterogeneity]; MCE) ( ).

Techniques:

Journal: Fluorine in Heterocyclic Chemistry Volume 2

Article Title: Fluorine-Containing Diazines in Medicinal Chemistry and Agrochemistry

doi: 10.1007/978-3-319-04435-4_7

Figure Lengend Snippet: The structures of Methotrexate ( 272 ), Sitagliptin ( 273 ) and Metformin ( 274 )

Article Snippet: Fig. 11 The structures of Methotrexate ( 272 ), Sitagliptin ( 273 ) and Metformin ( 274 ) Gemigliptin ( 12 ) was developed by LG Life Sciences as an inhibitor of dipeptidyl peptidase 4 (DPP-4) – a target of oral drugs used to treat used to treat type 2 diabetes (characterized by high blood glucose in the context of insulin resistance and relative insulin deficiency) [ ].

Techniques:

Journal: Drug Design, Development and Therapy

Article Title: A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects

doi: 10.2147/DDDT.S75980

Figure Lengend Snippet: Plasma dipeptidyl peptidase 4 (DPP-4) activity after a single oral administration of gemigliptin at 50 mg and metformin at 1,000 mg given as fixed-dose combination or separate tablets

Article Snippet: Gemigliptin (Zemiglo ® , LG Life Sciences, Seoul, South Korea) is a potent, selective, competitive, and long-acting DPP-4 inhibitor that was approved for use in patients with T2DM in June 2012 in Korea.

Techniques: Clinical Proteomics, Activity Assay

Journal: Drug Design, Development and Therapy

Article Title: A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects

doi: 10.2147/DDDT.S75980

Figure Lengend Snippet: Mean plasma dipeptidyl peptidase 4 (DPP-4) activity after a single oral administration of gemigliptin at 50 mg and metformin at 1,000 mg given as fixed-dose combination or separate tablets. ( A ) Mean percent inhibition–time profiles. ( B ) Area under the plasma DPP-4 activity–time curve from 0 to 48 hours post-dose (AUEC 0–48 h ); and ( C ) Maximum inhibition of DPP-4 activity (I max ). Note: The error bars in ( A ) denote the standard deviations. ( B and C ) The different symbols and lines represent different subjects assessed in the study. Abbreviations: h, hours; min, minutes; mOD, milli optical density.

Article Snippet: Gemigliptin (Zemiglo ® , LG Life Sciences, Seoul, South Korea) is a potent, selective, competitive, and long-acting DPP-4 inhibitor that was approved for use in patients with T2DM in June 2012 in Korea.

Techniques: Clinical Proteomics, Activity Assay, Inhibition

Journal: Drug Design, Development and Therapy

Article Title: A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects

doi: 10.2147/DDDT.S75980

Figure Lengend Snippet: Mean plasma concentration–time profiles of ( A ) gemigliptin and ( B ) metformin after a single oral administration at 50 mg and 1,000 mg, respectively, given as fixed-dose combination or separate tablets. Notes: The error bars denote the standard deviations. Insets show the linear scale. Abbreviation: h, hours.

Article Snippet: Gemigliptin (Zemiglo ® , LG Life Sciences, Seoul, South Korea) is a potent, selective, competitive, and long-acting DPP-4 inhibitor that was approved for use in patients with T2DM in June 2012 in Korea.

Techniques: Clinical Proteomics, Concentration Assay

Journal: Drug Design, Development and Therapy

Article Title: A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects

doi: 10.2147/DDDT.S75980

Figure Lengend Snippet: Pharmacokinetic parameters of gemigliptin and metformin after a single oral administration at 50 mg and 1,000 mg, respectively, given as fixed-dose combination or separate tablets

Article Snippet: Gemigliptin (Zemiglo ® , LG Life Sciences, Seoul, South Korea) is a potent, selective, competitive, and long-acting DPP-4 inhibitor that was approved for use in patients with T2DM in June 2012 in Korea.

Techniques: